1. Department of Hematological Malignancy, Institute of Medical Science, Tokai University, Isehara, Kanagawa, Japan;
2. Department of Infectious Diseases, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan;
3. Research Center for Cancer Stem Cell and
4. Department of Gastroenterology, Tokai University School of Medicine, Isehara, Kanagawa, Japan;
5. Department of Molecular Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan;
6. Department of Intractable Diseases, Institute of National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo, Japan;
7. Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan;
8. Malaysia-Japan Institute of Technology, Universiti Teknologi Malaysia, Kuala Lumpur, Malaysia;
9. Department of Biotechnology, Kulliyyah of Science, International Islamic University Malaysia, Kuantan, Malaysia;
10. Department of Hematology, School of Medicine, Kitasato University, Sagamihara, Kanagawa, Japan;
11. Department of Medical Genome Sciences, Graduate School of Frontier Sciences, and
12. Division of Cellular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan;
13. Department of Internal Medicine, Nishiwaki Municipal Hospital, Nishiwaki, Hyogo, Japan;
14. Department of Hematology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan;
15. Department of Medicine and Clinical Science, Gunma University, Maebashi, Gunma, Japan;
16. Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa, Japan;
17. Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, Saitama, Japan; and
18. AMED-PRIME, Japan Agency for Medical Research and Development, Tokyo, Japan